A
Adriane M Zernhelt
Researcher at Merck & Co.
Publications - 3
Citations - 1501
Adriane M Zernhelt is an academic researcher from Merck & Co.. The author has contributed to research in topics: Paclitaxel & MK-2206. The author has an hindex of 2, co-authored 3 publications receiving 1316 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas,Igor Puzanov,Reinhard Dummer,Dirk Schadendorf,Omid Hamid,Caroline Robert,F. Stephen Hodi,Jacob Schachter,Anna C. Pavlick,Karl D. Lewis,Lee D. Cranmer,Christian U. Blank,Steven J. O'Day,Paolo A. Ascierto,April K.S. Salama,Kim Margolin,Carmen Loquai,Thomas Eigentler,Tara C. Gangadhar,Matteo S. Carlino,Sanjiv S. Agarwala,Stergios J. Moschos,Jeffrey A. Sosman,Simone M. Goldinger,Ronnie Shapira-Frommer,Rene Gonzalez,John M. Kirkwood,Jedd D. Wolchok,Alexander M.M. Eggermont,Xiaoyun Nicole Li,Wei Zhou,Adriane M Zernhelt,Joy Lis,Scot Ebbinghaus,S. Peter Kang,Adil Daud +35 more
TL;DR: In this article, the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma were compared.
Journal ArticleDOI
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
L Rhoda Molife,Li Yan,Joanna Vitfell-Rasmussen,Adriane M Zernhelt,Daniel M. Sullivan,Philippe A. Cassier,Eric Y.H. Chen,Andrea Biondo,Ernestina Tetteh,Lillian L. Siu,Amita Patnaik,Kyriakos P. Papadopoulos,Johann S. de Bono,Johann S. de Bono,Anthony W. Tolcher,Susan Minton +15 more
TL;DR: MK-2206 plus carboplatin and paclitaxel, docetaxel or erlotinib was well-tolerated, with early evidence of antitumor activity, and two patients with squamous cell carcinoma of the head and neck demonstrated a complete and partial response.
Journal ArticleDOI
1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours
L. R. Molife,Susan Minton,J. Vitfell-Pedersen,Eric Y.H. Chen,Daniel C. Sullivan,L. Yan,Adriane M Zernhelt,Lillian L. Siu,J.S. de Bono,Anthony W. Tolcher +9 more